JOINN Laboratories Profit Jumps on Fair-Value Gains Despite Revenue Decline in 2025

JOINN Laboratories (China) Co., Ltd. Class H ( (HK:6127) ) has provided an announcement.

JOINN Laboratories reported audited 2025 results showing revenue of RMB1.66 billion, down 17.9% year-on-year, and gross profit of RMB281.06 million, a 44.4% decline, reflecting weaker top-line performance and margin pressure in its research services. Net assets attributable to equity shareholders rose 3.0% to RMB8.32 billion, underscoring a still-solid balance sheet despite softer operating metrics.

Profit for the year surged to RMB297.84 million from RMB69.76 million, mainly driven by a RMB514.27 million gain from changes in the fair value of biological assets and a swing in other gains and losses, masking the deterioration in underlying service profitability. The shift in earnings structure, with a greater contribution from fair-value gains rather than core operations, suggests investors and other stakeholders should scrutinize the quality and sustainability of JOINN’s profits in the current industry environment.

The most recent analyst rating on (HK:6127) stock is a Hold with a HK$28.00 price target. To see the full list of analyst forecasts on JOINN Laboratories (China) Co., Ltd. Class H stock, see the HK:6127 Stock Forecast page.

More about JOINN Laboratories (China) Co., Ltd. Class H

JOINN Laboratories (China) Co., Ltd. is a China-based contract research organization focused on providing preclinical and related research services to pharmaceutical and biotechnology companies. The group operates through its subsidiaries to support drug development with a range of laboratory-based services across domestic and international markets.

Average Trading Volume: 3,815,454

Technical Sentiment Signal: Hold

Current Market Cap: HK$23.84B

For a thorough assessment of 6127 stock, go to TipRanks’ Stock Analysis page.